Fundación Instituto Valenciano de Oncología

Patients’ and oncologists’ perspectives on shared decision-making and treatment communication in HR+/HER2 − advanced breast cancer: a multicountry survey

Hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) represents approximately 70% of all cases. In locally advanced or metastatic stages (laBC/mBC), patients’ quality of life (QoL) often worsens, making shared decision-maki...

Whole-genome sequencing of Reed-Sternberg cells identifies outcome determinants in Hodgkin lymphoma

Abstract Classical Hodgkin lymphoma (cHL) is a B-cell-derived malignancy characterized by rare Hodgkin and Reed–Sternberg (HRS) cells within an extensive inflammatory microenvironment. Although most patients achieve durable remission with first-line therapy, a subset relapse or e...

Trop-2 overexpression as a prognostic marker in early triple-negative breast cancer: results from the GEICAM_CIBOMA trial

Trophoblast cell-surface antigen 2 (Trop-2) is a key therapeutic target in metastatic triple-negative breast cancer (TNBC), yet its prognostic significance in early-stage disease remains poorly defined. We evaluated Trop-2 expression and its clinical impact within a sub-cohort of...